Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03370835 · ClinicalTrials.gov registry record · Phase 4
Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD
A Phase 4 study of Asthma and Pulmonary Disease, Chronic Obstructive, sponsored by VA Greater Los Angeles Healthcare System.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT03370835: Completed Phase 4 study of Asthma and Pulmonary Disease, Chronic Obstructive, sponsored by VA Greater Los Angeles Healthcare System.
NCT03370835 is a Phase 4 study of Asthma and Pulmonary Disease, Chronic Obstructive that has completed, run by VA Greater Los Angeles Healthcare System. The registered enrollment target is 21 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03370835, a Phase 4 study of Asthma and Pulmonary Disease, Chronic Obstructive, has completed, sponsored by VA Greater Los Angeles Healthcare System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
Use of beta-blockers has proven beneficial in patients with hypertension, heart failure, and in people who have suffered a heart attack. The use in patients who have Chronic Obstructive Pulmonary Disease (COPD) and reactive airway disease, however, has been limited due to possible side effects such as worsening of lung function or increasing airway spasms and asthma attacks. The purpose of this study is to find out if patients with COPD can tolerate being on a beta-blocker at doses recommended for the treatment of heart disease conditions. This study also seeks to find out if a selective beta-1 receptor beta-blocker is better than a non-selective beta-blocker in patients with mild to moderate COPD.
Conditions Studied
Interventions
- DRUG Carvedilol
- DRUG Metoprolol succinate ER
Study Locations (1)
California
- VA West Los Angeles Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2004-06 |
| Est. Completion | 2008-06 |
| Phase | Phase 4 |
What the finished NCT03370835 record still lists
NCT03370835 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Carvedilol is the first listed.
NCT03370835 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03370835 about?
NCT03370835 is a clinical study titled "Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD". Use of beta-blockers has proven beneficial in patients with hypertension, heart failure, and in people who have suffered a heart attack. The use in patients who have Chronic Obstructive Pulmonary Disease (COPD) and reactive airway disease, however, has been limited due to possible side effects such ...
What is the current status of trial NCT03370835?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2004-06. Estimated completion is 2008-06.
What conditions does trial NCT03370835 study?
This clinical trial studies the following conditions: Asthma, Pulmonary Disease, Chronic Obstructive, Adverse Effect of Beta-adrenoreceptor Antagonists.
What interventions are being tested in trial NCT03370835?
The interventions under investigation include: Carvedilol (DRUG), Metoprolol succinate ER (DRUG).
Who is sponsoring clinical trial NCT03370835?
This trial is sponsored by VA Greater Los Angeles Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03370835 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03370835's enrollment target sits among peer trials
21 337th of 374 higher than 38 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia